Literature DB >> 25882872

Intussusception and Monovalent Rotavirus Vaccination in Singapore: Self-Controlled Case Series and Risk-Benefit Study.

Chee-Fu Yung1, Siew Pang Chan2, Sally Soh3, Adriana Tan4, Koh Cheng Thoon5.   

Abstract

OBJECTIVE: To investigate the association between monovalent human rotavirus vaccine (RV1) and intussusception among Asian infants and the impact of older age of vaccination. To perform risk-benefit analysis of RV1 vaccination programs in Singapore. STUDY
DESIGN: We performed a self-controlled case series by extracting intussusception cases in infants aged <12 months from hospital databases (2005-2012) and with vaccination histories from a national immunization registry. Relative incidences were calculated by comparing incidence during defined risk periods after vaccination with times outside these periods. In the risk benefit analysis, we estimated excess intussusception hospitalization in relation to the number of infants vaccinated for hypothetical vaccination coverage scenarios.
RESULTS: There were 86 infants hospitalized with intussusception; 20 cases had received at least 1 dose of RV1. Nearly all (19) had received their first dose at age >12 weeks old. The age-adjusted relative incidence of intussusception in the 1- to 7-day period post dose one was 8.36 (95% CI 2.42-28.96). Of all childhood hospitalizations because of rotavirus, 71% (570 cases) could be prevented with 90% vaccination coverage. There would be approximately 1 excess intussusception case per 65,000 infants vaccinated.
CONCLUSIONS: Risk of intussusception increases about 8-fold during 1-7 days after receipt of first dose RV1 in infants of Chinese, Malay, and Indian ethnicity in Singapore, Asia. High vaccine coverage program in Singapore would be beneficial with only a low risk of excess intussusception. The relative risk of intussusception post-RV1 vaccination is not higher in Asia despite differences in background intussusception incidence compared with US and Australia, or older age of vaccination.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25882872     DOI: 10.1016/j.jpeds.2015.03.038

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  34 in total

Review 1.  Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines.

Authors:  Olufemi Samuel Folorunso; Olihile M Sebolai
Journal:  Vaccines (Basel)       Date:  2020-06-27

2.  Risk of Intussusception After Rotavirus Vaccination.

Authors:  Judith Koch; Thomas Harder; Rüdiger von Kries; Ole Wichmann
Journal:  Dtsch Arztebl Int       Date:  2017-04-14       Impact factor: 5.594

3.  Immune response and protective efficacy of the S particle presented rotavirus VP8* vaccine in mice.

Authors:  Ming Xia; Pengwei Huang; Xi Jiang; Ming Tan
Journal:  Vaccine       Date:  2019-06-11       Impact factor: 3.641

4.  Incidence and epidemiology of intussusception among children under 2 years of age in Chenzhou and Kaifeng, China, 2009-2013.

Authors:  Na Liu; Catherine Yen; Tao Huang; Pengwei Cui; Jacqueline E Tate; Baoming Jiang; Umesh D Parashar; Zhao-Jun Duan
Journal:  Vaccine       Date:  2018-02-10       Impact factor: 3.641

5.  Rotavirus vaccines: current global impact and future perspectives.

Authors:  Eleanor Burnett; Catherine Yen; Jacqueline E Tate; Umesh D Parashar
Journal:  Future Virol       Date:  2016-10       Impact factor: 1.831

6.  Age at First Rotavirus Vaccination and Risk of Intussusception in Infants: A Public Health Modeling Analysis.

Authors:  Chee Fu Yung; Chia Yin Chong; Koh Cheng Thoon
Journal:  Drug Saf       Date:  2016-08       Impact factor: 5.606

Review 7.  Approaches to monitoring intussusception following rotavirus vaccination.

Authors:  Jacqueline E Tate; Umesh D Parashar
Journal:  Expert Opin Drug Saf       Date:  2018-12-26       Impact factor: 4.250

Review 8.  Novel vaccine safety issues and areas that would benefit from further research.

Authors:  Daniel A Salmon; Paul Henri Lambert; Hanna M Nohynek; Julianne Gee; Umesh D Parashar; Jacqueline E Tate; Annelies Wilder-Smith; Kenneth Y Hartigan-Go; Peter G Smith; Patrick Louis F Zuber
Journal:  BMJ Glob Health       Date:  2021-05

9.  Effects of rotavirus NSP4 protein on the immune response and protection of the SR69A-VP8* nanoparticle rotavirus vaccine.

Authors:  Cunbao Liu; Pengwei Huang; Dandan Zhao; Ming Xia; Weiming Zhong; Xi Jiang; Ming Tan
Journal:  Vaccine       Date:  2020-12-11       Impact factor: 4.169

10.  Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus.

Authors:  Ming Xia; Chao Wei; Leyi Wang; Dianjun Cao; Xiang-Jin Meng; Xi Jiang; Ming Tan
Journal:  Sci Rep       Date:  2016-05-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.